Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Next Previous
Trial Profile

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Therapeutic Use
  • Sponsors Exelixis

    • Most Recent Events

    • 20 Oct 2017 Results assessing efficacy and tolerability of cabozantinib [XL 184] in patients with advanced solid tumours, with multi-cohorts of patients with metastatic hormone-refractory prostate cancer, ovarian cancer and breast cancer, were published in the European Journal of Cancer.
    • 26 Jul 2017 Results (N=70) of ovarian carcinoma cohort published in the European Journal of Cancer
    • 01 Mar 2017 Results from the hepatocellular carcinoma (n=41) cohort published in the Annals of Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top